Patrick Scanlon, DO
Internal Medicine · Methuen, MANPI 1669635694
Payments from drug & device makers
Across 480 payments — averaging $149.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$32K
- Sanofi$31K
- AstraZeneca$4K
- GSK$2K
- Inspire Medical Systems, Inc.$571
- Mylan Specialty L.p.$539
- plus $3K from 25 others
What the payments were for
- Consulting fees$13,62919%
- Speaking & faculty fees$43,65461%
- Travel & lodging$3,4175%
- Food & beverage$10,86915%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 45 | $31,794 |
| Sanofi | 32 | $30,831 |
| AstraZeneca | 147 | $3,611 |
| GSK | 94 | $1,609 |
| Inspire Medical Systems, Inc. | 8 | $571 |
| Mylan Specialty L.p. | 30 | $539 |
| Amgen | 24 | $501 |
| Baxter Healthcare | 13 | $330 |
| Regeneron Healthcare Solutions, Inc. | 17 | $326 |
| Inari Medical, Inc. | 1 | $179 |
| Grifols USA, LLC | 11 | $174 |
| Viatris Specialty LLC | 13 | $164 |
| Philips North America LLC | 4 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $119 |
| Harmony Biosciences LLC | 5 | $106 |
| Actelion Pharmaceuticals US, Inc. | 4 | $102 |
| Johnson & Johnson | 3 | $101 |
| United Therapeutics Corporation | 5 | $96 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| Electromed, Inc. | 3 | $54 |
| Novartis | 2 | $42 |
| Abiomed | 1 | $39 |
| Insmed, Inc. | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Pfizer | 2 | $31 |
| Verona Pharma, Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| EKOS Corporation | 1 | $20 |
| Pulmonx Corporation | 1 | $19 |
| 3b Medical, Inc. | 1 | $15 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$26,329
- OFEV$6,415
- FASENRA$647
- TEZSPIRE$474
- BREZTRI$473
- Inspire$427
- AIRSUPRA$366
- SYMBICORT$192
- FLOWTRIEVER CATHETER, S$179
- CT THROMBECTOMY SYSTEM KIT$179
How this compares
$71,681 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 879 | $716,784 |
| Dupixent PenDupilumab | 150 | $603,981 |
| OfevNintedanib Esylate | 14 | $181,536 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 238 | $180,896 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 205 | $127,077 |
| Breo ElliptaFluticasone/Vilanterol | 180 | $91,068 |
| Spiriva RespimatTiotropium Bromide | 101 | $73,056 |
| Incruse ElliptaUmeclidinium Bromide | 151 | $59,886 |
| NucalaMepolizumab | 11 | $59,518 |
| Pirfenidone | 16 | $36,325 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 80 | $23,342 |
| SymbicortBudesonide/Formoterol Fumarate | 75 | $19,582 |
| Wixela InhubFluticasone Propion/Salmeterol | 146 | $18,522 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 569 | $17,937 |
| Spiriva HandihalerTiotropium Bromide | 18 | $17,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Nucala | $1,609 | $1,064,3541,450 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $31,794 | $281,508159 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,611 | $200,478313 claims |
| MerckDulera | $13 | $15,67443 claims |
| PfizerEliquis | $31 | $6,73111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Methuen
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
- Ryan SullivanCambridge$8.5M
- Xiuning leBoston$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.